ArticleBMC microbiology2025
From cholera to food poisoning: exploring the antidiarrheal activity of a multi-species water-based probiotic product.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diarrheal diseases are a leading cause of morbidity and mortality worldwide. Given the rising prevalence of antimicrobial resistance among causative diarrheal pathogens, there is an increasing imperative to explore alternative therapeutic strategies. In this study, the potential of Symprove™ (a water-based probiotic product) against diarrheal pathogens, V. cholerae, E. coli, S. aureus, and L. monocytogenes was evaluated. Investigations were carried out using isothermal microcalorimetry and colony counting. The experimental setup consisted of individual cultures and co-incubations of the pathogens and probiotic formulation. Growth curves were obtained for all setups using a thermal activity monitor, and colony counts were performed after 24–48 h for both probiotic organisms and pathogens. The growth curves obtained revealed that co-incubation of E. coli and S. aureus with the probiotic formulation showed a slightly delayed onset of growth for the pathogens although these pathogens were faster growing than the probiotic. For L. monocytogenes, the thermal growth curves showed dominance of the probiotic formulation. Corresponding colony counts revealed significantly reduced bacterial numbers after 48 h when the pathogens were co-incubated with the probiotic formulation. Co-incubating V. cholerae with the probiotic formulation showed a significant reduction in pathogen numbers after 24 h and no counts after 48 h. These findings indicate the possible inhibitory effect of the probiotic formulation and highlight the therapeutic potential of probiotics as alternative approach to conventional antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.